| + |
bevacizumab | down-regulates activity 
binding
|
VEGFD |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259887 |
|
|
Homo sapiens |
Colorectal Cancer Cell |
| pmid |
sentence |
| 15961063 |
Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
bevacizumab | down-regulates activity
binding
|
VEGFB |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259885 |
|
|
Homo sapiens |
Colorectal Cancer Cell |
| pmid |
sentence |
| 15961063 |
Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
bevacizumab | down-regulates activity
binding
|
VEGFA |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259884 |
|
|
Homo sapiens |
Colorectal Cancer Cell |
| pmid |
sentence |
| 15961063 |
Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
bevacizumab | down-regulates activity
binding
|
VEGFC |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259886 |
|
|
Homo sapiens |
Colorectal Cancer Cell |
| pmid |
sentence |
| 15961063 |
Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
bevacizumab
